Despite significant advancements in treatments for lung cancer, many patients...
Professor Wakelee from Stanford, United States, presented the final DFS...
The final analysis of the DESTINY-Lung02 trial, a dose-blinded phase 2...
A presentation at ASCO focused on the quality of life of patients undergoing...
At the ASCO Congress, the results of a study on a non-invasive tool to assess...
The AEGEAN and Checkmate 77T trials investigated perioperative chemotherapy...
The ADAURA trial, which investigated adjuvant osimertinib for patients with...
In the pivotal, phase III CheckMate 816 study, neoadjuvant nivolumab in...
Prof Christophe Dooms, thoracic oncologist at UZ Leuven and Prof Martin Reck,...
Over the last decades, therapeutic advances for patients with limited-stage...